A startup conceived to improve emergency treatment for epileptic seizures based on a father’s fears for his son’s safety has been sold to a large biopharma company also making a rescue therapy for the dangerous attacks.

UCB (UCBJF), based in Brussels, on Friday said it has acquired Engage Therapeutics of Summit, N.J., for $125 million upfront, with potential milestone payments of up to $145 million. Engage is developing Staccato Alprazolam, a combination of an inhaler and the drug alprazolam, that has been tested in a Phase 2 clinical trial to see if it can quickly halt an epileptic seizure. UCB won Food and Drug Administration approval last year for its own inhalable form of midazolam, which, like alprazolam, belongs to the class of drugs called benzodiazepines.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy